Over 7,000 breast cancer resection surgeries have been performed to date using Dion's technology, which is implemented in 27 states in the US and 11 medical centers throughout Israel. Studies have shown that the use of MarginProbe helped to reduce the risk of repeat surgery by about 60%.
The medical device company, Dion Medical reports a significant milestone in the history of the company from Caesarea: selection of the 100th medical center in the MarginProbe system developed by Dion.
MarginProbe allows surgeons, who perform breast cancer removal (lumpectomy), to identify in real time the cancerous tissues. Through a test carried out by the surgeon using the MarginProbe, the resection margins can be easily examined and if cancer cells are detected, the surgeon immediately performs an expansion of the operated area, thus preventing the need for further surgery.
Over 7000 breast cancer resection surgeries have been performed to date using Dion's technology, which is implemented in 27 states in the US and 11 medical centers throughout Israel.
"Since we built an independent sales system in the US towards the end of 2013, the company has achieved double-digit growth every quarter, for 8 consecutive quarters", says Gil Rosen, Dion's VP of global marketing.
"It is encouraging to see how quickly the market adopted such an innovative system as the MarginProbe," said Dan Shamshoni, founder and CEO of Dion. Healthcare providers in the US are now aligning themselves with the growing demand for quality and optimization of results. As pioneers who lead an improvement in the results of cancer surgery, and especially as those who reduce the frequency of repeat operations in surgery to remove breast cancer, we are well positioned to fulfill these needs.'
The tissue characterization technology, intraoperatively, and its application through the MarginProbe system, is the first and only one currently approved by the American Drug Administration (FDA). The integration of technology in operating rooms allows hospitals to offer breast cancer patients the greatest chance of achieving clean resection margins during breast cancer tumor resection surgeries. The system uses RF spectroscopy, in a measurement procedure that lasts less than 5 minutes, to identify whether or not there are cancerous cells at the resection margin. Studies have shown that the use of MarginProbe helped to reduce the risk of repeat surgery by about 60%.
4 תגובות
And it is also in the interest of the owners of the money to ignore me for 20 years.
Sorry. I did not consider this possibility and I apologize. But I think there is nothing wrong with something like interest funding the site, but this is your site and your choice.
I didn't get paid otherwise I would have written that it was marketing content. In this case, the distribution company, and those who want to relate and those who don't don't. I receive dozens of press releases a day and the first priority is scientific news. Regardless, the site could have brought in much more and also allowed me to hire, for example, a deputy editor if the people who make the decisions did not belong to the old generation who do not understand how the Internet works and continue to think as before that only large media outlets exist. There is no connection between the importance and quality of the site and its income, if anything - there is an opposite connection.
The article is a bit informative, but we need to finance the website provided to us as a free, legitimate service. That's why there may not have been many responses. In the 60th, the article deserves comments. If indeed it reduces the need for repeated analysis by 60%, it is obvious that either the company's sales will increase, or someone will copy and distribute. Like Bill Gates did to Steve Jobs. It is important to clarify a point, as far as I understand it does not reduce by XNUMX% the chance of morbidity but of repeat surgery. It is likely that there are no statistics yet on the chance of morbidity.